Antithyroid drug use in early pregnancy and birth defects: Time windows of relative safety and high risk?

European Journal of Endocrinology

Volumn 171, Issue 1, 2014, Pages

  Laurberg, Peter ^a,b   Andersen, Stine Linding ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; ANTITHYROID AGENT;

BIRTH DEFECT; CHOANA ATRESIA; DENMARK; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ESOPHAGUS ATRESIA; FACE DYSMORPHIA; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEART SEPTUM DEFECT; HUMAN; HYPERTHYROIDISM; JAPAN; OMPHALOCELE; OMPHALOMESENTERIC DUCT ANOMALY; ORGANOGENESIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK FACTOR; SKIN APLASIA; TERATOGENESIS; URINARY SYSTEM DEFECT; CONGENITAL DISORDER; ENDOCRINE DISEASE; FEMALE; MALE; PREGNANCY; PREGNANCY COMPLICATION;

ANTITHYROID AGENTS; CARBIMAZOLE; CONGENITAL ABNORMALITIES; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PROPYLTHIOURACIL;

EID: 84903532030     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0135     Document Type: Review

References (44)

1. Laurberg P, Bournaud C, Karmisholt J & Orgiazzi J. Management of Grave's hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. European Journal of Endocrinology 2009 160 1-8. (doi:10.1530/EJE-08-0663)
2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011 21 1081-1125. (doi:10.1089/thy.2011.0087)
3. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2012 97 2543-2565. (doi:10.1210/jc.2011-2803)
4. Cooper DS & Laurberg P. Hyperthyroidism in pregnancy. Lancet. Diabetes & Endocrinology 2013 1 238-249. (doi:10.1016/S2213-8587(13)70086-X)
5. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB & Laurberg P. Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. European Journal of Endocrinology 2011 164 801-809. (doi:10.1530/EJE-10-1155)
6. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G & Torring O. TSH-receptor autoimmunity in Grave's disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. European Journal of Endocrinology 2008 158 69-75. (doi:10.1530/EJE-07- 0450)
7. ClementiM, Di Gianantonio E, Pelo E, Mammi I, Basile RT & Tenconi R. Methimazole embryopathy: delineation of the phenotype. American Journal of Medical Genetics 1999 83 43-46. (doi:10.1002/(SICI)1096-8628(19990305)83: 1〈43::AID-AJMG8〉3.0.CO;2-C)
8. Foulds N, Walpole I, Elmslie F & Mansour S. Carbimazole embryopathy: an emerging phenotype. American Journal of Medical Genetics. Part A 2005 132A 130-135. (doi:10.1002/ajmg.a.30418)
9. Taylor PN & Vaidya B. Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyrotoxicosis in pregnancy. European Thyroid Journal 2012 1 176-185. (doi:10.1159/000342920)
10. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y et al. Treatment of Grave's disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. Journal of Clinical Endocrinology and Metabolism 2012 97 2396-2403. (doi:10.1210/jc.2011-2860)
11. Andersen SL, Olsen J, Wu CS & Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish Nationwide Study. Journal of Clinical Endocrinology and Metabolism 2013 98 4373-4381. (doi:10.1210/jc.2013- 2831)
12. Moore KL, Persaud TVN & Torchia MG. Human birth defects. In The Developing Human: Clinically Oriented Embryology, 9th edn, pp 471-501. Philadelphia, PA, USA: Saunders/Elsevier, 2013.
13. Milham SJ & Elledge W. Maternal methimazole and congenital defects in children. Teratology 1972 5 125-126. (doi:10.1002/tera.1420050117)
14. Mandel SJ, Brent GA & Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994 4 129-133. (doi:10.1089/thy.1994.4.129)
15. Cassina M, Dona M, Di Gianantonio E & Clementi M. Pharmacologic treatment of hyperthyroidism during pregnancy. Birth Defects Research. Part A, Clinical and Molecular Teratology 2012 94 612-619. (doi:10.1002/bdra.23012)
16. Chen CH, Xirasagar S, Lin CC, Wang LH, Kou YR & Lin HC. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG: an International Journal of Obstetrics and Gynaecology 2011 118 1365-1373. (doi:10.1111/j.1471-0528.2011.03019.x)
17. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y & Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid 2013 23 758-765. (doi:10.1089/thy.2012.0488)
18. Benavides VC, Mallela MK, Booth CJ, Wendler CC & Rivkees SA. Propylthiouracil is teratogenic in murine embryos. PLoS ONE 2012 7 e35213. (doi:10.1371/journal.pone.0035213)
19. van Veenendaal NR, Ulmer B, Boskovski MT, Fang X, Khokha MK, Wendler CC, Blum M & Rivkees SA. Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos. FASEB Journal 2013 27 684-691. (doi:10.1096/fj.12-218073)
20. Carle A, Pedersen IB, Perrild H, Ovesen L, Jorgensen T & Laurberg P. High age predicts low referral of hyperthyroid patients to specialized hospital departments: evidence for referral bias. Thyroid 2013 23 1518-1524. (doi:10.1089/thy.2013.0074)
21. Leung AK & Robson WL. Association of preauricular sinuses and renal anomalies. Urology 1992 40 259-261. (doi:10.1016/0090-4295(92)90487-H)
22. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P,McDougall IR,MontoriVM, Rivkees SAet al.Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011 21 593-646. (doi:10.1089/thy.2010.0417)
23. Diez-Delgado Rubio J, Belmonte Martin MJ, Calvo Bonachera MD & Lopez Candel E. Aplasia cutis as a teratogenic effect of methimazole. Anales Españoles de Pediatría 1999 51 290-292.
24. Rodriguez-Garcia R. Bilateral renal agenesis (Potter's syndrome) in a girl born to a hyperthyroid mother who received methimazole in early pregnancy. Ginecología y Obstetricia de México 1999 67 587-589.
25. Di Gianantonio E, Schaefer C, Mastroiacovo PP, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A et al. Adverse effects of prenatal methimazole exposure. Teratology 2001 64 262-266. (doi:10.1002/tera. 1072)
26. Ferraris S, Valenzise M, Lerone M, Divizia M T, Rosaia L, Blaid D, Nemelka O, Ferrero GB & Silengo M. Malformations following methimazole exposure in utero: an open issue. Birth Defects Research. Part A, Clinical and Molecular Teratology 2003 67 989-992. (doi:10.1002/bdra.10098)
27. Karg E, Bereg E, Gaspar L, Katona M & Turi S. Aplasia cutis congenita after methimazole exposure in utero. Pediatric Dermatology 2004 21 491-494. (doi:10.1111/j.0736-8046.2004.21417.x)
28. Valdez RM, Barbero PM, Liascovich RC, De Rosa LF, Aguirre MA & Alba LG. Methimazole embryopathy: a contribution to defining the phenotype. Reproductive Toxicology 2007 23 253-255. (doi:10.1016/j.reprotox.2006.11.007)
29. Baid SK & Merke DP. Aplasia cutis congenita following in utero methimazole exposure. Journal of Pediatric Endocrinology & Metabolism 2007 20 585-586. (doi:10.1515/JPEM.2007.20.5.585)
30. Iwayama H, Hosono H, Yamamoto H, OshiroM& Ueda N. Aplasia cutis congenita with skull defect in a monozygotic twin after exposure to methimazole in utero. Birth Defects Research. Part A, Clinical and Molecular Teratology 2007 79 680-684. (doi:10.1002/bdra.20395)
31. Barbero P, Valdez R, Rodriguez H, Tiscornia C, Mansilla E, Allons A, Coll S & Liascovich R. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. American Journal of Medical Genetics. Part A 2008 146A 2390-2395. (doi:10.1002/ajmg.a.32497)
32. KoenigD, SpreuxA,Hieronimus S,ChichmanianRM,Bastiani F, Fenichel P & Brucker-Davis F. Birth defects observed withmaternal carbimazole treatment: six cases reported to Nice's Pharmacovigilance Center. Annales d'Endocrinologie 2010 71 535-542. (doi:10.1016/j.ando.2010.07.001)
33. Douchement D, Rakza T, Holder M, Bonne NX & Fayoux P. Choanal atresia associated with tracheoesophageal fistula: the spectrum of carbimazole embryopathy. Pediatrics 2011 128 e703-e706. (doi:10.1542/peds.2010-0945)
34. Gripp KW, Kuryan R, Schnur RE, Kothawala M, Davey LR, Antunes MJ, Reichard KW, Schneider A & Hall BD. Grade 1 microtia, wide anterior fontanel and novel type tracheo-esophageal fistula in methimazole embryopathy. American Journal of Medical Genetics. Part A 2011 155A 526-533. (doi:10.1002/ajmg.a. 33705)
35. Ting YH, Zhou Y & Lao TT. Carbimazole embryopathy in a Chinese population: case series and literature review. Birth Defects Research. Part A, Clinical andMolecular Teratology 2013 97225-229. (doi:10.1002/bdra.23117)
36. Tan T, Constantinides H & Mitchell TE. The preauricular sinus: a review of its aetiology, clinical presentation and management. International Journal of Pediatric Otorhinolaryngology 2005 69 1469-1474. (doi:10.1016/j. ijporl.2005.07.008)
37. Seoud M, Nassar A, Usta I, Mansour M, Salti I & Younes K. Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. American Journal of Perinatology 2003 20 59-62. (doi:10.1055/s-2003-38320)
38. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y & Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clinical Endocrinology 1984 20 695-700. (doi:10.1111/j.1365-2265.1984.tb00119.x)
39. Laurberg P. Remission of Grave's disease during anti-thyroid drug therapy. Time to reconsider the mechanism? European Journal of Endocrinology 2006 155 783-786. (doi:10.1530/eje.1.02295)
40. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S & Weeke J. Goitre size and outcome of medical treatment of Grave's disease. Acta Endocrinologica 1986 111 39-43. (doi:10.1530/acta.0.1110039)
41. Momotani N, Hisaoka T, Noh J, Ishikawa N & Ito K. Effects of iodine on thyroid status of fetus versus mother in treatment of Grave's disease complicated by pregnancy. Journal of Clinical Endocrinology and Metabolism 1992 75 738-744. (doi:10.1210/jcem.75.3.1517362)
42. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ & Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstetrics and Gynecology 2006 107 337-341. (doi:10.1097/01.AOG.0000197991.64246.9a)
43. Kimura M, Seki T, Ozawa H, Ishihara T, Komatsu M, Tajiri S, Yanagi H, Nishina M, Noh JY, Fukagawa M et al. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Grave's disease who wished to become pregnant. Endocrine Journal 2013 60 383-388. (doi:10.1507/endocrj.EJ12-0212)
44. Cooper DS & Rivkees SA. Putting propylthiouracil in perspective. Journal of Clinical Endocrinology and Metabolism 2009 94 1881-1882. (doi:10.1210/jc.2009-0850)